Someone had early access to the filing! Hehehe
$Redhill Biopharma (RDHL.US)$ RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on August 1, 2024, the publication of positive Phase 3 study data for RHB-104 in the treatment of Crohn's disease. The study, which included 331 patients and was conducted across over 100 sites globally, demonstrated a 64% increase in efficacy when RHB-104 was added to the standard of care compared to the standard of care alone. The primary endpoint of clinical remission at week 26 was achieved by 36.7% of patients treated with RHB-104 versus 22.4% of those receiving a placebo, with a safety profile similar to placebo. The study's lead investigator, Dr. David Y. Graham, highlighted the potential of RHB-104 as an effective treatment for Crohn's disease, which could serve as an add-on therapy for patients not responding to current treatments. The Crohn's disease market was valued at over $13 billion in 2023. RedHill's CEO, Dror Ben-Asher, expressed the company's commitment to advancing the development of RHB-104 and exploring partnership models to bring this treatment to market
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Salmon Klein : so there is no fresh money for the company... I thought private issuer is when the company is receiving funds
Trytosaveabit OP Salmon Klein : That was a few days ago if I remember correctly? This filing is from just this morning